| Literature DB >> 33387149 |
Christine Little1, Mathilda Alsen2, Joshua Barlow1, Leonard Naymagon3, Douglas Tremblay3, Eric Genden2, Samuel Trosman2, Laura Iavicoli4, Maaike van Gerwen5,6.
Abstract
There have been limited data assessing the influence of disadvantaged socioeconomic status (SES) on the incidence and clinical outcomes of COVID-19 patients within the diverse communities of the United States. Here, we aim to investigate the association between poverty level, as an indicator of SES, and COVID-19 related clinical outcomes including hospitalization and all-cause mortality. This retrospective cohort study included 3528 patients with laboratory confirmed COVID-19 seen at a large New York City health system between March 1, 2020 and April 1, 2020. Data for neighborhood level poverty was acquired from the American Community Survey 2014-2018 and defined as the percent of residents in each ZIP code whose household income was below the federal poverty threshold (FPT): 0% to < 20% below FPT (low poverty) and > 20% below FPT (high poverty). COVID-19 positive patients who resided in high poverty areas were significantly younger, had a higher prevalence of comorbidities and were more likely to be of female gender or a racial minority when compared to individuals living in low poverty areas. Residence in a high poverty area was not associated with an increased risk of COVID-19 related hospitalization and was found to be associated with a decreased risk of in-hospital mortality. This study suggests the existence of an unequal socioeconomic gradient in the demographic and clinical presentation of COVID-19 patients including differences in age, gender and race between poverty groups. Further studies are needed to fully assess the intersectionality of SES with the COVID-19 pandemic.Entities:
Keywords: COVID-19; Poverty; SARS-CoV-2; Socioeconomic status
Mesh:
Year: 2021 PMID: 33387149 PMCID: PMC7775835 DOI: 10.1007/s10900-020-00944-3
Source DB: PubMed Journal: J Community Health ISSN: 0094-5145
Demographic and clinical characteristics of COVID-19 positive patients
| Characteristic | All (n = 3528) | Low poverty (n = 2090) | High poverty (n = 1438) | P value |
|---|---|---|---|---|
| Age (years ± SD) | 57.03 (± 18.2) | 58.3 (± 18.2) | 55.2 (± 18.1) | |
| Age groups (years) | ||||
| <40 | 762 (21.6) | 411 (19.7) | 351 (24.4) | |
| 40–60 | 1088 (30.8) | 674 (32.2) | 486 (33.8) | |
| >60 | 1678 (47.5) | 1005 (48.1) | 601 (41.8) | |
| Gender | ||||
| Male | 1930 (54.7) | 1197 (57.3) | 733 (51.0) | |
| Female | 1598 (45.3) | 893 (42.7) | 705 (49.0) | |
| Race | ||||
| Non-Hispanic white | 908 (25.7) | 677 (32.4) | 231 (16.1) | |
| Non-Hispanic black | 974 (27.6) | 516 (24.7) | 458 (31.9) | |
| Other | 1445 (41.0) | 760 (36.4) | 685 (47.6) | |
| Unknown | 201 (5.7) | 137 (6.6) | 64 (4.5) | |
| Smoking status | 0.166 | |||
| Current | 185 (5.2) | 101 (4.8) | 84 (5.8) | |
| Former | 696 (19.7) | 404 (19.3) | 292 (20.3) | |
| Never | 2039 (57.7) | 1238 (59.2) | 801 (55.7) | |
| Unknown | 608 (17.2) | 347 (16.6) | 261 (18.2) | |
| BMI > 30* | 1020 (28.8) | 548 (26.2) | 472 (32.8) | |
| Comorbidities | ||||
| Cardiovascular disease | ||||
| Hypertension | 1589 (45) | 931 (44.6) | 658 (45.8) | 0.477 |
| Atrial fibrillation | 294 (8.3) | 173 (8.3) | 121 (8.4) | 0.885 |
| Coronary artery disease | 426 (12.1) | 260 (12.4) | 166 (11.5) | 0.422 |
| Congestive heart failure | 280 (7.9) | 149 (7.1) | 131 (9.1) | |
| PVD | 135 (3.8) | 68 (3.3) | 67 (4.7) | |
| Chronic respiratory disease | ||||
| Asthma | 407 (11.5) | 198 (9.5) | 209 (14.5) | |
| COPD | 161 (4.6) | 95 (4.6) | 66 (4.6) | 0.951 |
| Metabolic disease | ||||
| Diabetes | 1012 (28.7) | 563 (26.9) | 449 (31.2) | |
| Hypothyroidism | 238 (6.8) | 153 (7.3) | 85 (5.9) | 0.101 |
| CVA/TIA | 208 (5.9) | 124 (5.9) | 84 (5.8) | 0.910 |
| Prior VTE | 123 (3.5) | 56 (2.7) | 67 (4.7) | |
| Chronic kidney disease | 336 (9.5) | 166 (7.9) | 170 (11.8) | |
| Cancer | 295 (8.4) | 182 (8.7) | 113 (7.9) | 0.370 |
| Cirrhosis | 55 (1.6) | 31 (1.5) | 24 (1.7) | 0.662 |
| Dementia | 200 (5.6) | 126 (6.0) | 74 (5.2) | 0.265 |
| Admitted to Hospital | 1904 (54.0) | 1140 (54.6) | 764 (53.1) | 0.699 |
Bold values indicate statistical significance (p < 0.05)
BMI body mass index, COPD chronic obstructive pulmonary disease, CVA/TIA cerebral vascular accident or transient ischemic attack, PVD peripheral vascular disease, SD standard deviation, VTE: venous thromboembolism
*683 patients had unknown or missing BMI data
Clinical characteristics and outcomes of patients hospitalized for COVID-19
| Characteristic or clinical outcome | All (n = 1904) | Low poverty (n = 1140) | High poverty (n = 764) | P value |
|---|---|---|---|---|
| Age (years ± SD) | 65.8 (± 16.0) | 66.8 (± 15.7) | 62.3 (± 16.8) | |
| Age groups (years) | ||||
| <40 | 151 (7.9) | 68 (6.0) | 83 (10.9) | |
| 40–60 | 532 (27.9) | 294 (25.8) | 238 (31.1) | |
| >60 | 1221 (64.1) | 778 (68.2) | 443 (58.0) | |
| Gender | 0.115 | |||
| Male | 1118 (58.7) | 686 (60.2) | 432 (56.5) | |
| Female | 786 (41.3) | 454 (39.8) | 332 (43.5) | |
| Race | ||||
| Non-Hispanic white | 459 (24.1) | 345 (30.3) | 114 (14.9) | |
| Non-Hispanic black | 523 (27.5) | 268 (23.5) | 255 (33.4) | |
| Other | 835 (43.9) | 473 (41.5) | 362 (47.4) | |
| Unknown | 87 (4.6) | 54 (4.7) | 33 (4.3) | |
| BMI > 30* | 653 (36.6) | 367 (34.7) | 286 (39.3) | |
| Comorbidities† | ||||
| Asthma | 218 (11.5) | 113 (9.9) | 105 (13.7) | |
| Prior VTE | 83 (4.4) | 38 (3.3) | 45 (5.9) | |
| Chronic kidney disease | 285 (15) | 146 (12.8) | 139 (18.2) | |
| Hospital Course | ||||
| Clinical measures | ||||
Mechanical ventilation required | 497 (26.1) | 331 (29.0) | 166 (21.7) | |
| Bleeding event | 30 (1.6) | 15 (1.3) | 15 (2.0) | 0.266 |
| Overt thrombosis | 47 (2.5) | 30 (2.6) | 17 (2.2) | 0.575 |
| Renal replacement therapy | 128 (6.7) | 86 (7.5) | 42 (5.5) | 0.081 |
| Clinical outcomes | ||||
| Died | 595 (31.3) | 419 (36.7) | 176 (23.0) | |
| Alive at last follow up | 1309 (68.7) | 721 (63.3) | 588 (77.0) | |
Mean time to death (days ± SD)‡ | 10.2 (± 8.7) | 9.8 (± 8.6) | 11.2 (± 8.8) | 0.066 |
Mean length of follow up for surviving patients (days ± SD) | 21.38 (± 13.50) | 20.87 (± 13.5) | 22.01 (± 13.4) | 0.125 |
Bold values indicate statistical significance (p < 0.05)
BMI body mass index, SD standard deviation, VTE venous thromboembolism
*118 patients had unknown or missing BMI data
†Only comorbidities that were found to differ significantly between poverty groups in patients hospitalized with COVID-19 are reported. All other comorbidities reported in Table 1 were assessed and none found to be significant
‡Calculation of mean time to death included only patients who were deceased at the time of last follow up
Odds ratio for hospitalization and Hazard Ratio for all-cause mortality among COVID-19 positive patients (n = 3528)
| Unadjusted OR (95% CI) | Adjusted OR* (95% CI) | Unadjusted HR (95% CI) | Adjusted HR† (95% CI) | |
|---|---|---|---|---|
| Poverty: high vs. low | 0.95 (0.83–1.08) | 0.98 (0.83–1.17) | 0.55 (0.46–0.66) | 0.61 (0.51–0.73) |
| Age | − | − | ||
| Gender: male vs. female | − | − | ||
| Race | ||||
| NHB vs. NHW | − | − | 1.18 (0.94–1.49) | |
| Other vs. NHW | − | − | 1.12 (0.90–1.39) | |
| BMI > 30 | − | − | ||
| Congestive heart failure | − | − | − | |
| Peripheral vascular disease | − | 1.09 (0.68–1.74) | − | − |
| Asthma | − | 0.97 (0.76–1.25) | − | 0.88 (0.66–1.17) |
| Chronic kidney disease | − | − | 1.11 (0.87–1.40) | |
| Prior VTE | − | 0.90 (0.57–1.41) | − | 0.80 (0.53–1.22) |
Bold values indicate statistical significance (p < 0.05)
BMI body mass index, CI confidence interval, HR hazard ratio, NHB non-Hispanic black, NHW non-Hispanic white, OR Odds ratio, VTE venous thromboembolism
*Adjusted for age (continuous; years), gender, race, BMI > 30, CHF, PVD, asthma, CKD and prior VTE
†Adjusted for age (continuous; years), gender, race, BMI > 30, asthma, CKD and prior VTE
Fig. 1Survival probability among patients hospitalized with COVID-19 in low poverty and high poverty areas